Galapagos Reports Positive Phase 2 Trial Data of Crohn’s Disease Drug Filgotinib at ECCO Congress

Galapagos Reports Positive Phase 2 Trial Data of Crohn’s Disease Drug Filgotinib at ECCO Congress
Galapagos recently presented data from the FITZROY Phase 2 clinical trial of filgotinib for Crohn’s disease at the 11th ECCO Congress in Amsterdam. Prof. Séverine Vermeire, lead investigator of the trial, presented the analysis of the 10-week treatment study. In the FITZROY trial, 174 patients were treated with either a placebo or  200 milligrams of filgotinib in

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *